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Abstract: We have now at our disposal the new rapid-acting insulin analogs, of which insulin 
lispro was the first to become commercially available. While the differences in pharmacokinetic 
and pharmacodynamic characteristics are indisputable, the clinical benefits attained by these 
changes have not been as clear. In the present review, we discuss the structure, pharmacology, 
and landmark studies related to insulin lispro. The clinical characteristics of insulin lispro are 
compared with those of insulin regular and other insulin analogs in different clinical situations. 
Also included are the aspects of quality of life and cost-effectiveness that may modify the modern 
practitioner’s decision to adopt one type of insulin over another.
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Background
We have now at our disposal the new rapid-acting insulin analogs which mimic the first 
phase of pancreatic insulin secretion in response to a meal. These rapid-acting insulin 
analogs, when combined with long-acting insulin or used in a continuous subcutaneous 
insulin infusion pump, mimic the pattern of endogenous pancreatic insulin secretion 
both in the basal and prandial states. This is the “basal-bolus” therapy paradigm and is 
the closest physiologically matched insulin replacement therapy among the injectable 
forms. Basal-bolus therapy allows tighter blood sugar control and possibly reduces 
the risk of severe hypoglycemia associated with conventional insulin therapy using 
human regular insulin.
At present, there are three rapid-acting insulin analogs used clinically and available 
on the market. These insulin analogs are lispro (Eli-Lilly), aspart (Novo-Nordisk), and 
glulisine (Sanofi-Aventis). They are marketed, respectively, under the brand names 
Humalog®, Novolog®, and Apidra®. All of the rapid-acting insulin analogs were 
developed using recombinant DNA technology by modifying one or more amino 
acids in the insulin molecule. This modification led to faster subcutaneous absorption 
compared with human regular insulin. All of the insulin analogs are approved for use 
subcutaneously using a pen device or syringe as well as insulin pumps. Among these 
commercially available rapid-acting insulin analogs, insulin lispro was the first to be 
developed and has been available in the US since 1996. Insulin lispro will be the topic 
of this review.
Human regular insulin exists as hexamers in solution. Once injected subcutaneously, 
the hexamers dissociate into dimers and monomers before being absorbed into the sys-
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subcutaneously, it dissociates faster into monomers compared 
with human regular insulin. As such, it results in an earlier and 
much greater peak than human regular insulin. This property is 
shared by insulin aspart as well as glulisine. In insulin lispro, 
this property is achieved by transposition of the amino acid, 
proline, at position 28 of the B chain to that of lysine at position 
29 (see Figure 1). This change causes insulin lispro to have 
fewer tendencies for self-association by primarily disrupting 
the formation of dimers, causing it to dissociate more quickly 
into monomers once injected into the subcutaneous tissue.1 
Although this amino acid transposition alters the structure 
of native human insulin, leading to faster dissociation of the 
hexamer molecule into monomers, it does not alter the capacity 
of insulin lispro to bind to the insulin receptor and to dissociate 
from the insulin receptor when compared with human regular 
insulin. It is worth mentioning that the two other rapid analogs 
also have structural changes that allow the rapid onset of action 
seen with insulin lispro. In insulin aspart, proline is substituted 
with the charged aspartic acid at B28 position, and in insulin 
glulisine, asparagine at position B3 is replaced by lysine, and 
lysine in position B29 is replaced by glutamic acid.
Pharmacokinetics and 
pharmacodynamics
The development of rapid-acting insulin analogs was driven 
by the need to change the parameters controlling the self-
association of the insulin hexamers. This would, in principle, 
affect the speed of absorption of insulin and its pattern of 
activity in the body. From the first studies published about 
insulin lispro in the 1990s, the difference was clear. Studies in 
healthy volunteers showed that the insulin lispro concentration 
peaked at almost twice the concentration of human regular 
insulin and did so in half the time (see Figure 2 for details). 
Insulin lispro has a shorter half-life compared with human 
regular insulin, and it was originally thought that this could 
affect its potency. However, glucose clamp studies showed 
that both the total infused glucose (450.8 ± 161.8 mmol ver-
sus 454.7 ± 167.4 mmol) and the area under the curve of the 
glucose levels over time were equivalent for both insulin lispro 
and human regular insulin2 (see Table 1 for details).
In subsequent years, with the development of other insulin 
analogs, a number of studies compared the respective charac-
teristics of the various analogs in different clinical settings. 
One study5 observed that after subcutaneous injection of 
either analog, insulin lispro showed more rapid absorption, 
reached a peak concentration earlier (40 ± 3 minutes versus 
49 ± 3 minutes; P = 0.01) and showed a more rapid decline 
than insulin aspart (decrease of free insulin concentration 
from peak concentration to 50% of the maximum concentra-
tion, 113 ± 10 minutes versus 154 ± 14 minutes; P = 0.02). 
The authors of this study believed this finding may be of 
clinical importance.
B28
Lys
B29
Pro
Figure 1 Structure of insulin lispro, showing the amino acid modifications that 
produce insulin lispro.
Modified from PDB iD: 3e7Y Timofeev vi, Baidus AN, Kislitsyn YA, Juranova iP.
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Figure 2 (A) Concentration of insulin lispro reaches its peak in half of the time that 
human regular insulin takes to reach its peak. (B) The highest glucose infusion rate is 
reached in half of the time for insulin lispro compared with human regular insulin.
Reprinted with permission from Holleman MD, Hoekstrra JBL. insulin Lispro. N Engl 
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An randomized double-blind study in healthy males 
comparing insulin lispro and aspart6 showed a 10-minute 
difference in the time to maximal reduction, favoring insulin 
aspart, but no difference in the glucose control response. 
Two studies done in patients with type 1 diabetes mellitus5,7 
showed very similar peak times for both insulin aspart and 
lispro (approximately 40 minutes in both studies) and time 
to reach 50% of the peak (approximately 20 minutes). The 
consistent results over two separate studies point towards 
a real biological equivalence between these two insulin   
analogs.
Another study investigated if there was a difference in the 
metabolic effects between insulin aspart and lispro among 
patients with type 1 diabetes mellitus. After subcutaneous 
injection of an equal amount of each insulin into the same 
patients, no statistically significant difference was found 
between the two insulin analogs in terms of its effect on 
carbohydrate metabolism (glucose uptake, glucose oxidation, 
and endogenous glucose production) and lipid metabolism 
(plasma free fatty acid, ketone body levels, and free fatty 
acid oxidation). There were also no significant changes in 
c-peptide and glucagon levels in this study.8
Among healthy nondiabetic volunteers, it has been shown 
that insulin glulisine is biochemically equivalent to insulin 
lispro, but it has a faster onset of action than insulin lispro 
in the first hour after subcutaneous injection (area under the 
curve 0–1 hour [mg/kg] 69.22 ± 38.59 for insulin glulisine 
versus 45.95 ± 28.84 mg/kg for insulin lispro).9 This effect 
was observed independent of body mass index and dose, and 
was observed in Caucasian and Chinese volunteers.9,10 During 
an euglycemic glucose clamp trial among patients with type 1 
diabetes mellitus, insulin lispro and glulisine had similar 
effects on suppression of endogenous glucose production, 
as well as glucose uptake and free fatty acid, glycerol, and 
lactate levels compared with human regular insulin.
Another aspect of the comparative studies was the use 
of insulin lispro as part of a combination regimen (rapid-
acting insulin/basal insulin). When mixed with human 
neutral protamine hagedorn insulin (NPH), insulin lispro is 
not stable over time, precluding prolonged storage of this 
mixture. Because of this, insulin lispro has been coupled with 
protamine to produce neutral protamine lispro. Its pharma-
cokinetic and glucodynamic characteristics are comparable 
with those of neutral protamine hagedorn when tested in a 
glucose clamp study that involved eight healthy volunteers,11 
although those given neutral protamine lispro initially had a 
slightly greater glucose requirement than those given neutral 
protamine   hagedorn.12 The difference was small and the clini-
cal significance is probably not significant.
In comparative studies that utilized insulin lispro as part 
of a combination regimen (rapid-acting insulin/basal insulin), 
an euglycemic glucose clamp study using healthy subjects 
that compared different concentrations of insulin lispro/neu-
tral protamine lispro (25/75, 50/50, and 75/25) showed that 
independently of the mixture, the maximal metabolic effect 
was reached after 2 hours, its amplitude determined by the 
relative amount of rapid-acting insulin lispro. The glucose 
requirement after 6 hours was affected by the concentration 
of neutral protamine lispro, but the area under the curve at 
6 hours was equivalent between all the preparations.13
Table 1 Comparison of human regular insulin and insulin lispro2–4
Human regular insulin (SC) Insulin lispro (SC)
Pharmacokinetics Maximum serum insulin level (pM) 308 ± 132 698 ± 227
Time to peak concentration (minutes) 101 ± 40 42 ± 20
Area under the serum insulin concentration  
versus time curve (nmol ∙ min-1∙ L-1)
72.7 ± 12.3 71.4 ± 14.6
Pharmacodynamics Onset of action (minutes) 30–60 5–15
Peak of action (hours) 2–3 0.5–1.5
Duration of action (hours) 6–10 4–5
Maximum glucose infusion rate (mmol/minute) 2.20 ± 1.01 3.10 ± 1.19
Time to maximum glucose infusion rate (minutes) 179 ± 93 99 ± 39
Total amount of glucose infused (mmol) 454.7 ± 167.4 450.8 ± 161.8
Receptor affinity  
and mitogenicity
Insulin receptor affinity (%) 100 84 ± 6
Insulin receptor off rate (%) 100 100 ± 11
Metabolic potency (%) 100 82 ± 3
IGF-1 receptor potency (%) 100 156 ± 16
Mitogenic potency (%) 100 66 ± 10
Abbreviations: iGF-1, insulin growth-like factor 1; SC, subcutaneous.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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There are some differences in the interaction of insulin 
lispro with the insulin-like growth factor 1 (IGF-1) receptor 
in comparison with human regular insulin and other analogs. 
The affinity of insulin lispro for the IGF-1 receptor is 1.5-
fold that of human insulin,14 but its mitogenic potential is 
slightly less than that of human insulin when evaluated using 
human osteosarcoma cells (Saos/B10),4 indicating that the 
slightly elevated IGF-1 receptor affinity is not sufficient to 
provide a mitogenic stimulus, at least with Saos/B10 cell 
lines. Using human mammary epithelial cells provided 
similar results.15 The differences in IGF-1 receptor binding 
affinity can be accounted for by the structural amino acid 
transposition changes that increase the homology of insulin 
lispro to IGF-1.14
In summary, insulin lispro has been shown to have a more 
rapid concentration peak and a shorter half-life compared 
with human regular insulin. This change results in a shorter 
time to maximal glucose reduction and similar potency, with 
a shorter duration of action compared with human regular 
insulin. There are no major differences in comparison with 
other rapid-acting insulin analogs.
Clinical studies
In trials that compare insulin regimens, hemoglobin A1c 
(HbA1c) measurement, fasting and postprandial glucose, 
and hypoglycemia occurrence are the common measurable 
outcomes. HbA1c reflects the overall glycemic exposure of 
the preceding 3 months. It is influenced by both fasting blood 
glucose as well as postprandial plasma glucose values. At 
higher HbA1c values (.8.4%), the fasting plasma glucose 
contribution predominates, and at lower HbA1c the postpran-
dial glucose contribution predominates.16 The introduction of 
the rapid-acting analogs, by the nature of their rapid onset of 
action, would better control blood glucose excursions after 
meals and, in theory, should improve HbA1c in the setting of 
patients with adequate basal insulin coverage (ie, reasonable 
fasting glucose levels).
As shown in Table 1, human regular insulin, when com-
pared with insulin lispro (as well as insulin aspart and glu-
lisine) has a slower onset of activity (30–60 minutes) and has 
a longer duration of action (6–8 hours). Because of its slower 
onset of action, human regular insulin needs to be admin-
istered at least 30 minutes before meals to match the blood 
glucose excursion during meals. In reality, most patients 
do not follow the correct timing of human regular insulin 
administration in relation to a meal.17 Because of its longer 
duration of action, human regular insulin can lead to late 
postprandial hypoglycemia. In contrast, insulin lispro (as well 
as insulin glulisine and aspart) can be injected immediately 
before, during, or immediately after meals because it has a 
faster onset of action. This property of the rapid-acting insulin 
analogs offers the greatest advantage to patients in terms of 
practicality and flexibility that otherwise cannot be achieved 
with the human regular insulin formulation.
Below are described the comparative efficacy and safety 
studies of insulin lispro versus human regular insulin and 
other rapid-acting analogs.
Insulin regular versus lispro
Numerous studies have shown that the rapid-acting insulin 
analogs achieve lower postprandial blood glucose levels 
when compared with human regular insulin.18–21 A review by 
Gough22 showed that rapid-acting insulin analogs compared 
with human regular insulin resulted in consistently lower 
postprandial blood glucose levels. In patients with type 1 
diabetes mellitus, postprandial blood glucose levels were 
0.6–2.0 mmol/L lower in subjects on insulin lispro compared 
with those on human regular insulin. Among patients with 
type 2 diabetes mellitus on a basal-bolus regimen, postpran-
dial blood glucose levels were 48%–53% lower compared 
with human insulin, with no significant or fewer episodes 
of hypoglycemia in favor of insulin lispro.
In one of the largest trials that has utilized insulin lispro in 
patients with type 1 diabetes mellitus, insulin lispro has been 
shown to achieve mean overall postprandial blood glucose 
levels that were significantly lower than for human regular 
insulin (postprandial rise in serum glucose was reduced at 
one hour by 1.3 mmol/L and at 2 hours by 2.0 mmol/L in 
patients treated with insulin lispro [P , 0.001]). The reduc-
tion in postprandial blood glucose was also shown in other 
studies.19,20,23 The same is true for patients with type 2 diabetes 
mellitus, either as part of oral therapy or patients already on 
insulin therapy.19,24–26 The reduction in postprandial blood 
glucose levels was seen whether insulin lispro was given as 
part of a basal-bolus regimen, premixed insulin with human 
or analog insulin, or in combination with oral agents.
Despite reduction in postprandial hyperglycemia, a 
Cochrane meta-analysis27 that compared rapid-acting insulin 
analogs with human regular insulin found a weighted mean 
difference in HbA1c of only -0.1% in favor of rapid-acting 
analogs in patients with type 1 diabetes mellitus. There was 
no difference in HbA1c in patients with type 2 diabetes mel-
litus. In this meta-analysis, 49 randomized controlled trials 
were included, and 37 studies used insulin lispro. In assessing 
the HbA1c reduction in patients with type 1 diabetes mellitus, 
22 studies were included in the analysis, of which 16 studies Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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compared insulin lispro with human regular insulin. The tri-
als included showed significant   heterogeneity (P = 0.02). The 
analysis for type 2 diabetes mellitus included five studies. The 
meta-analysis also reported that fewer severe hypoglycemic 
episodes occurred among patients with type 1 diabetes mel-
litus given rapid-acting insulin compared with those who 
were given human regular insulin. The incidence of severe 
hypoglycemia was 21.8 (median) episodes per 100 person-
years for rapid-acting insulin analogs versus 46.1 for human 
regular insulin. For patients with type 2 diabetes mellitus, the 
incidence of severe hypoglycemia was 0.3 (median) episodes 
per 100 person-years for insulin analogs and 1.4 for human 
regular insulin.
Additional and more recent studies have focused on 
the impact of the basal-bolus regimen approach in patients 
with type 1 diabetes mellitus, and these were compared in 
a 2010 meta-analysis.28 In this meta-analysis, 28 articles 
were included, of which 17 studies compared insulin lispro 
with human regular insulin. The majority of the studies used 
neutral protamine hagedorn as the basal insulin. Overall, the 
average change in HbA1c from baseline to study end for rapid-
acting insulin analogs compared with human regular insulin 
was -0.16% and -0.08%, respectively, with a tendency 
towards greater HbA1c improvement with rapid-acting insulin 
analogs. The authors of this meta-analysis postulated that the 
minimal improvement in HbA1c may have been due to the use 
of neutral protamine hagedorn as the basal insulin in most of 
the studies, as well as the limitations of the studies included, 
which were primarily aimed at demonstrating noninferiority 
of the rapid-acting insulin analogs. The authors of this meta-
analysis did not pool the data for incidence of hypoglycemia, 
but most of the studies reported lower or similar incidences of 
total or nonsevere hypoglycemia episodes with rapid-acting 
insulin analogs compared with human regular insulin. The 
prevalence of severe hypoglycemia in the included studies 
was low. It should be borne in mind that the rates of hypo-
glycemia in the studies included in this meta-analysis tended 
to be lower for rapid-acting insulin analogs, and this was 
accompanied by HbA1c improvement, albeit minimal.
In a review that compared an all-analog insulin regimen 
with an all-human insulin regimen, HbA1c reduction in favor 
of all-analog insulin was seen in two studies (7.88% versus 
8.11%; P , 0.001 in favor of aspart/detemir and 7.5%   versus 
8.0%; P , 0.001 in favor of glargine/lispro).29,30 These two 
studies also showed a similar or decreased overall incidence 
(21% reduction, P = 0.036) of hypoglycemia as well as 
nocturnal hypoglycemic events (up to a 55%   reduction, 
P , 0.001). A third study31 did not show a significant 
difference among those given glargine/lispro and neutral 
protamine hagedorn/human regular insulin in terms of an 
HbA1c reduction, but did show a decrease in nocturnal hypo-
glycemic events by 43% in favor of insulin lispro. Several 
studies have also shown a lower occurrence of hypoglycemia 
with the use of rapid-acting insulin analogs compared with 
human regular insulin.18,19,31,32
Perhaps the greatest benefit of rapid-acting insulin ana-
logs compared with human regular insulin, in terms of HbA1c 
reduction and occurrence of hypoglycemia, comes from 
data derived from its use among insulin pump users with 
type 1 diabetes mellitus. It has been shown in continuous 
subcutaneous insulin pump users that insulin lispro provides 
a similar or greater reduction of HbA1c, with no increase 
or less incidence of hypoglycemia compared with human 
regular insulin.33–37 In one of these studies,37 the reduction in 
HbA1c was -0.62% ± 0.13% for insulin lispro compared with 
-0.09% ± 0.15% for human regular insulin. The incidence 
of hypoglycemia with blood glucose , 3.0 mmol/L did not 
differ significantly between the two insulins, but the incidence 
of blood glucose , 2.0 mmol/L was significantly reduced 
with insulin lispro (0.05 ± 0.05 versus 0.47 ± 0.19 per month, 
P , 0.05). The theoretical disadvantage of insulin lispro 
given by continuous subcutaneous insulin pump infusion, 
especially among patients with type 1 diabetes mellitus, is 
the propensity to develop diabetic ketoacidosis sooner if the 
pump is disconnected for whatever reason. This is because 
of the shorter duration of action of insulin lispro. However, 
this was not seen in a study by Attia et al, who showed that 
the rate of rise in plasma glucose or serum ketone formation 
is similar between human regular insulin and insulin lispro 
when the pump is disconnected for 6 hours.38
The use of insulin lispro in an inpatient setting in a 
general medicine ward has been investigated recently. The 
use of prandial human regular insulin was compared with 
rapid-acting insulin analogs in regards to the timing of insu-
lin delivery (target time) in relation to meals, patient safety 
(mostly rates of hypoglycemia), and glucose control. A higher 
rate of target time in the insulin lispro group was achieved 
compared with the human regular insulin group (88.9% 
versus 70.1%, P , 0.001). The rate of hypoglycemia was 
lower for insulin lispro compared with human regular insulin 
(1.85% versus 15%, P , 0.001). The rate of hyperglycemia 
(blood glucose . 180 mg/dL) was similar in both groups 
(68.2% versus 59.8%, P = 0.224), but severe hyperglyce-
mia (.300 mg/dL) was higher for the insulin lispro group 
(28.9% versus 12.9%, P = 0.003).39 Among hospitalized 
patients, whose meal intake can be unpredictable for various Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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medical and logistical reasons, the use of rapid-acting insulin 
analogs, allowing nurses to time the injections at the start of 
each meal, may lead to better patient outcomes than the use 
of human regular insulin.
Insulin lispro versus aspart
Among patients with type 1 diabetes mellitus on continu-
ous subcutaneous insulin infusions, one study35 showed no 
differences in HbA1c or rates of hypoglycemic episodes per 
patient per month between those using human regular, aspart, 
or lispro insulins, although they noted a trend towards slightly 
lower rates and number of hypoglycemic episodes in favor 
of insulin aspart.
Another study involving patients with type 1 diabetes 
mellitus on continuous insulin infusion40 assessed the effect 
of both insulin lispro and aspart on glucose variability 
after each was given as a normal-wave bolus 15 minutes 
before a standard meal, as measured using a continuous 
glucose monitoring system. This was a randomized, con-
trolled, open-label, crossover clinical trial. The result of this 
study showed that both insulin lispro and aspart compar-
ably reduced the early postprandial glucose value (30 and 
60 minutes), but the late postprandial glucose value (90 and 
120 minutes) continued to decrease more with insulin lispro, 
with significantly lower levels compared with insulin aspart 
(9.3 ± 36.6 mg/dL at 90 minutes; -12 ± 43.6 mg/dL at 
120 minutes). Although the authors concluded that daily 
glucose variability was comparable between the two insulin 
analogs, postprandial glucose was more stable with insulin 
aspart when given as a normal premeal bolus. Based on their 
data, the authors of this study recommended that insulin 
aspart and lispro should be given with a different bolus distri-
bution in order to achieve comparable postprandial glycemic 
control. In contrast, a study41 reviewing the consequences 
of delayed line change in continuous subcutaneous insulin 
infusions showed no difference in glucose control between 
insulin lispro and aspart.
A head-to-head comparison between biphasic formula-
tions of insulin aspart (BIAsp 30: 30% aspart, 70% protami-
nated aspart), biphasic insulin lispro 25 (mix 25; 25% lispro, 
75% protaminated lispro) and biphasic human insulin 30 
(BHI) (30% human regular insulin, 70% neutral protamine 
hagedorn insulin) was done in patients with type 2 diabetes 
mellitus treated with insulin. Both analogs were injected 
immediately before the test meal, while BHI was given 
15 minutes before the test meal. Both analogs were supe-
rior to BHI in terms of serum glucose excursion 0–5 hours 
after the meal, and BIAsp 30 was superior to lispro mix 25 
(16.6 ± 4.4 versus 18.9 ± 6.1 mmol/L × hour, P , 0.05). In 
this study, glucose excursion during the late postprandial 
phase was also lower with BIAsp compared with lispro mix 
25 (8.3 ± 2.6 versus 9.7 ± 3.8 mmol/L × hour, P , 0.05) but 
not during the early phase.42 It should be borne in mind that 
the protaminated ratio of the two analogs used in this study 
was different, and whether the difference was due to this 
alone, an intrinsic difference between the two analogs, or a 
combination of the two, is unclear.
Insulin lispro versus glulisine
In 672 patients with type 1 diabetes mellitus on a basal bolus 
regimen utilizing glargine as the basal insulin, insulin lispro 
and glulisine were shown over a 26-week period to achieve 
a similar reduction in HbA1c (adjusted mean change from 
baseline -0.14% in both groups) as well as no relevant dif-
ference between the two groups in reports of symptomatic 
hypoglycemia (3.64 ± 4.49 [glulisine] versus 3.48 ± 4.38 
[lispro] events/month). Although this study demonstrated 
that insulin glulisine achieves glycemic control equivalent 
to that of insulin lispro, it also showed that the basal insulin 
dose was relatively unchanged from baseline in the glulisine 
group but increased in the insulin lispro group (0.12 IU 
[glulisine] versus 1.82 IU [lispro]; P = 0.0001). The clinical 
significance of this difference remains to be established.43 
Among pediatric patients with type 1 diabetes mellitus, insu-
lin glulisine has also been shown to be as effective as insulin 
lispro in baseline-to-endpoint HbA1c change (0.10% versus 
0.16%, respectively) with similar episodes of symptomatic 
hypoglycemia.44
When administered by insulin pump to patients with 
type 1 diabetes mellitus, insulin glulisine was not superior 
to insulin lispro in terms of unexplained hyperglycemia or 
perceived catheter set occlusion.45 Insulin glulisine was also 
associated with a higher frequency of symptomatic hypo-
glycemia compared with insulin lispro in patients with type 
1 diabetes mellitus which the authors suggested may have 
been due to overdosing.45 When administered preprandially 
to patients with type 2 diabetes mellitus, insulin glulisine 
underwent significantly faster absorption than insulin lispro 
during the first 30 minutes after a meal.46 However, this 
did not translate into overall statistically significant differ-
ences in the plasma glucose profile between the two analog 
insulins.
Insulin lispro in fixed combinations
In the US, neutral protamine lispro is available premixed 
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Humalog® mix 75/25 (75% neutral protamine lispro and 
25% insulin lispro) and Humalog® mix 50/50 (50% neutral 
protamine lispro and 50% insulin lispro). Because premixed 
insulin contains both basal and prandial components in dif-
ferent proportions, most patients prefer to use it because 
it can enable twice-daily injections compared with four 
injections per day for the basal-bolus regimen. Unlike 
human premixed insulin, which should be injected at least 
30 minutes prior to a meal, premixed analog insulin can 
be injected within 15 minutes of a meal, which is more 
convenient for some patients.
When compared with human insulin 70/30, lispro 75/25 
has been proven to decrease postprandial blood glucose 
levels and excursion significantly among patients with 
type 2 diabetes mellitus, which is expected of analogs, as 
described above.47–49 Despite this, premixed insulin lispro 
was not shown to have an advantage over human insulin 
70/30 in reducing HbA1c among patients with type 1 or type 
2 diabetes mellitus.12,50 However, in a Japanese treat to target 
study,51 it was shown that use of premixed lispro 50/50 was 
able to decrease HbA1c significantly compared with premixed 
human insulin (mean HbA1c 7.59% ± 0.44% at the start of 
the study and 7.24% ± 0.49% at 4 months, P , 0.05 for 
the analog group versus mean HbA1c 7.33% ± 0.58% at the 
start of the study and 7.29% ± 0.65% at 4 months in the 
premixed human insulin group). A previous study by the 
same group comparing biphasic insulin aspart 70/30 and 
human insulin 70/30 did not show a beneficial effect on 
HbA1c level in insulin-naïve patients. They hypothesized that 
the difference they were able to show in the second study 
may have been due to their patient population (ie, Japanese) 
and a higher consumption of high glycemic index food (ie, 
rice) that required a greater amount of rapid-acting insulin 
analog, and that the difference in HbA1c reduction among 
insulin-naïve patients treated with human insulin or analog 
may be small and difficult to detect.
Lispro 75/25 given twice a day was shown to be superior 
to glyburide 15 mg daily in terms of HbA1c reduction (8.5% 
with lispro 75/25 versus 9.4% with glyburide; P = 0.001).52
When compared with once-daily insulin glargine in 
patients with type 2 diabetes mellitus treated for 16 weeks 
in treat-to-target trials, lispro 75/25 given twice daily 
has been shown to be superior in terms of HbA1c reduc-
tion (7.54% ± 0.87% versus 8.14% ± 1.03%, P , 0.001). 
A higher proportion of patients (42% versus 18%; P = 0.002) 
also met the treatment goal of HbA1c , 7% with lispro 75/25 
given twice daily compared with insulin glargine given once 
daily.53
Use in pregnancy
In 1997, two cases were reported of a possible teratogenic 
effect of insulin lispro used in pregnant patients with type 1 
diabetes mellitus.54 The observations made in these case 
reports were not made in subsequent studies. Studies that 
used insulin lispro in patients with type 1, 2, or gestational 
diabetes mellitus have reported no increase in pregnancy 
complications compared with human regular insulin.55–57 
One meta-analysis that compared insulin lispro with human 
regular insulin in patients with type 1 diabetes mellitus found 
that there was no difference in metabolic control or perina-
tal outcome among patients who used insulin lispro during 
pregnancy compared with human regular insulin, aside from 
a higher rate of large-for-gestational age newborns among 
those who used insulin lispro during pregnancy (relative 
risk 1.38%, confidence interval 1.14–1.68).58 Comparable or 
improved glycemic control with a lower total insulin require-
ment and HbA1c during pregnancy was reported among 
patients with gestational as well as type 1 and 2 diabetes 
mellitus.56,57,59
Quality of life and cost-effectiveness
Health-related quality of life is a management outcome vari-
able that has been growing in importance in recent years. 
Although diabetes mellitus is recognized to be a disease 
that significantly affects quality of life in our patients,60,61 
there are scant data on how treatment with insulin analogs 
modifies it.
The largest and most comprehensive health-related 
quality of life trial for insulin lispro was a subsection of the 
original safety and efficacy study done by the Multicenter 
Insulin Lispro Study Group.62 This study compared health-
related quality of life over 12 months in patients taking 
insulin lispro with those taking human regular insulin, in 
the setting of an open-label multinational randomized trial 
involving 468 patients with type 1 diabetes mellitus and 474 
with type 2 diabetes mellitus. It showed that, for patients with 
type 1 diabetes mellitus, there was no statistically significant 
difference in outcomes, except in the domains of treatment 
satisfaction and treatment flexibility. In the case of patients 
with type 2 diabetes mellitus, there was no difference in any 
domain between the two therapies.
A much smaller (n = 30) randomized controlled trial 
compared twice-daily premixed human insulin versus the 
equivalent insulin lispro formulation.51 A similar improve-
ment in treatment convenience score was found, with no 
difference in quality of life data, although the follow-up time 
was much shorter (4 months).Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 submit your manuscript | www.dovepress.com
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Lastly, a follow-up of the ABCs of Diabetes study63 
evaluated the effect that treatment with insulin lispro had on 
quality of life in adolescents who were unable to maintain 
metabolic control with human regular insulin. It was found 
that adolescents in the insulin lispro group had significantly 
better diabetes self-efficacy and quality of life, but that satis-
faction with diabetes treatment was not associated with use of 
insulin lispro. In the last two studies, it is clear that issues with 
a small sample size could have affected their discriminative 
capacity, making a type 2 error a significant possibility.
Another important aspect in the evaluation of new medi-
cations is their cost-effectiveness, even moreso in the current 
cost-conscious health care environment. Few studies have 
looked at this issue in regards to rapid-acting insulin analogs, 
but recent studies have shed some light on it.
A cost-effectiveness study applying the Center for Out-
comes Research Diabetes Model to data obtained from meta-
analysis of randomized controlled trials showed that, for type 1 
diabetes mellitus, use of insulin lispro had an increased effi-
ciency that was associated with an incremental cost of almost 
30,000 Canadian dollars per quality-adjusted life-year.64 When 
the model was adjusted by including fear of hypoglycemia, the 
cost decreased to less than 2000   Canadian dollars. 
The analysis was repeated for type 2 diabetes mellitus, 
showing increased effectiveness for insulin lispro, but an even 
larger cost per quality-adjusted life-year (around 130,000 
dollars). The authors did caution that the model was very 
sensitive to variations in the level of fear of hypoglycemia 
or in the difference in HbA1c between the treatments, so any 
decisions made on the basis of these data have to take this 
into account.
One large objection to the previous approach is that 
subjects in randomized controlled trials may be very dif-
ferent from subjects who are seen in the day-to-day clinics. 
Also, there are clear differences in the types of patients who 
receive one type of insulin versus another, and this can clearly 
change the parameters when comparing the costs associated 
with each type of insulin. A study conducted using pharmacy 
claims data from 14 plans distributed over the US tried to 
avoid this by using a propensity score.65 This score, which 
indicates how likely a particular patient is to receive one type 
of therapy versus another, was used to match patients and 
balance the treatment groups at the start of the study. Over 
the course of a 12-month follow-up of 3664 subjects, it was 
found that patients using insulin lispro made significantly 
more office visits and filled more prescriptions compared with 
patients using human regular insulin. At the same time, these 
patients had significantly fewer inpatient   hospitalizations than 
the group of patients on human regular insulin. The total cost 
of all interventions (both inpatient and outpatient) showed 
cost savings for the insulin lispro group of 216 dollars (which 
was not found to be statistically significant). One significant 
limitation of this study is that they included patients in each 
insulin group if they had only one prescription filled for 
insulin during their time of participation in the study.
A later study by the same group, using data from a large 
managed care organization, tried to replicate the above 
results, while addressing the main concerns about the previ-
ous study.66 This was done by including patients who had at 
least three refills of insulin, and by stratifying the patients 
depending on their propensity score (instead of only match-
ing them by score). A total of 6436 patients were followed 
in this way for 12 months, and a similar pattern of a greater 
number of physician office visits was found in patients using 
insulin lispro, along with a larger total pharmacy cost (which 
was expected, given that insulin lispro is more expensive than 
human regular insulin), but a lower total medical cost (2327 
dollars) which was not found to be statistically significant. 
It is important to note that one limitation of the propensity 
score methodology is that factors that are not measured can 
significantly affect the scores obtained. Taking all these fac-
tors into account, insulin lispro seems to have an effectiveness 
similar or superior to that of human regular insulin, with an 
associated increase in cost that may be compensated by a 
lower number of hospitalizations.
Conclusion
Since its introduction in 1996, insulin lispro and other rapid-
acting analogs have proven to be safe and comparable or 
superior to human regular insulin in terms of HbA1c reduction 
and/or reducing the risk of hypoglycemia. The rapid onset 
of action of insulin lispro and the other analogs allows their 
injection around meal time, making them safer and easier to 
use in comparison with human regular insulin.
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